WebinarsNew
Deep DiveNew
Explore Business Standard
Divi's Laboratories Ltd on Saturday posted a sharp 63.57 per cent rise in net profit to Rs 1,127 crore in the September quarter due to higher revenues. The company posted a net profit of Rs 689 crore in the corresponding period of the previous fiscal year, a regulatory filing said. Revenue from operations rose 35.39 per cent to Rs 3,676 crore during the second quarter of FY27 from Rs 2,715 crore a year earlier, it said. Its total expenses rose to Rs 2,265 crore in the period under review from Rs 1,948 crore a year ago, it added. The company's net profit for the first half of the current fiscal year, however, declined 35.39 per cent to Rs 2,029 crore from Rs 2,568 crore in the year-ago period, the filing added.
Drug firm Divi's Laboratories on Monday said its profit after tax (PAT) increased 65 per cent to Rs 589 crore for the December quarter, on the back of robust sales across markets. The company had reported a profit after tax (PAT) of Rs 358 crore for the October-December quarter of last fiscal. Revenue from operations rose to Rs 2,319 crore in the third quarter as against Rs 1,855 crore in the year-ago period, Divi's Laboratories said in a regulatory filing. The drug firm noted a part of the Kakinada Project (Unit-III) commenced commercial operations from January 1, 2025. The rest of Kakinada project is being implemented and is expected to be operational in about six months, it added. "We have capitalised assets of Rs 433 crore for the quarter and of Rs 557 crore for the nine-month period of the current fiscal year. Of this, capitalisation for Kakinada Project is Rs 418 crore during the 9-month period," the drug firm stated. The company said its board has approved the re-appointme